FindTrial
Sign In

Calblock tablet postmarketing clinical study (Essential hypertensive patients with type 2 diabetes)

Calblock tablet postmarketing clinical study (Essential hypertensive patients with type 2 diabetes)

Status
Unknown
Phases
Phase 4
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCT1080220028
Enrollment
Unknown
Registered
2005-09-05
Start date
2005-09-05
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Mild-to-moderate essential hypertension with type 2 diabetes

Interventions

investigational material(s) Generic name etc : Calblock tablet(Azelnidipine)|Acecol tablet(Temocapril Hydrochloride) INN of investigational material : azelnidipine/Temocapril Therapeutic category code

Sponsors

DAIICHISANKYO Co.,Ltd.
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Inclusion criteria: -Patient, age 30-79 -Blood pressure: stable, mean SBP >= 140 and = 90 and <110 mmHg.

Exclusion criteria

Exclusion criteria: Exclusion criteria: -Secondary hypertension or malignant hypertension -Cerebrovascular disease and cardiovascular disease -Patient with poor glycemic control

Design outcomes

Primary

MeasureTime frame
Efficacy and safety—

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026